Elmiron Lawsuits Filed for Patients with Vision Loss Due to Elmiron Use
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
We are handling Elmiron lawsuits for patients who have suffered vision loss due to their use of Elmiron. These Elmiron lawsuits are filed against the drug companies responsible for Elmiron. This is because — despite a growing number of Elmiron-related vision loss case reports in the medical literature over the past few years — it was not until June 2020 that any warning about eye problems was included in the Elmiron drug label here in the US.
This Elmiron label change in June 2020 finally added some warnings for serious eye problems such as retinal pigmentary changes and pigmentary maculopathy. From our perspective, these warnings about Elmiron eye side effects were long overdue.
We are currently investigating possible Elmiron lawsuits for patients diagnosed with eye problems such as:
- Vision Loss / Blindness
- Maculopathy (pigmentary or retinal)
- Macular Degeneration
It is important to know that our Elmiron lawsuits for patients who have suffered vision loss are filed only against the pharmaceutical companies responsible for Elmiron — not the doctors who prescribed the Elmiron as a treatment for their bladder diseases.
Significantly, it is not necessary for the patient to have been using Elmiron regularly right up until the time when their Elmiron-related vision loss was diagnosed in order to file an Elmiron lawsuit. That is, unlike most other drug injury cases, the patient could have stopped using Elmiron months before a medical doctor was able to diagnose their eye problem.
Please feel free to contact us if we can be of assistance to you in regards to a possible Elmiron lawsuit.
We encourage you to submit an Elmiron Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, nor some other lawyer – about your case based on his many years of experience.
Most Recent Article About Elmiron
In the past few years, there are case reports of Elmiron (pentosan polysulfate sodium / “PPS”) causing eye problems such as retinal pigmentary changes and pigmentary maculopathy resulting in vision loss. The current body of medical literature suggests that perhaps Elmiron side effects risks related to the eye and vision — such as Elmiron-associated maculopathy — might be greater than the bladder disease treatment benefits.
To read more of this article, click below:
Here are two medical journal articles stating that there are Elmiron side effects risks for the eye and vision of patients using Elmiron:
- This article “Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium [Elmiron]”, published by the medical journal Ophthalmology in 2018, reported on six women who used Elmiron for treatment of their interstitial cystitis and later were diagnosed with pigmentary maculopathy which was attributed to their Elmiron use.
- From “Association of Macular Disease with Long-Term Use of Pentosan Polysulfate Sodium [Elmiron]: Findings from a U.S. Cohort”, published by the British Journal of Ophthalmology in 2019: “PPS [Elmiron] users had significantly increased odds of having atypical maculopathy . . . .”
And, next, here are two medical journal articles suggesting that the bladder disease treatment benefits of Elmiron are not that great:
- From “A Pilot Clinical Trial of Oral Pentosan Polysulfate [Elmiron] and Oral Hydroxyzine in Patients with Interstitial Cystitis”, published by the Journal of Urology in 2003: “The low global response rate for PPS [Elmiron] and hydroxyzine suggest that neither provided benefit for the majority of patients with IC.”
- From “Pentosan Polysulfate [Elmiron] for Treatment of Interstitial Cystitis/Bladder Pain Syndrome: Insights from a Randomized, Double-Blind, Placebo Controlled Study”, published by the Journal of Urology in 2015: “Results of this study in a broad population of patients with symptoms consistent with interstitial cystitis revealed no treatment effect vs. placebo for pentosan polysulfate sodium [Elmiron].”
We are currently investigating possible Elmiron drug injury lawsuits for patients diagnosed with a vision-related Elmiron side effect such as Elmiron-associated maculopathy.[Read article in full at original source]
Our earlier articles about Elmiron:
- Elmiron Lawsuits Being Filed Against Drug Companies for Elmiron-Related Eye Problems
- FDA Announces Elmiron Drug Safety-Related Labeling Changes
- Elmiron Potentially Linked to Severe Eye Disorders